We are adjusting our assumptions for Nicox's strategy for lead candidate NCX-470. We now assume the company will rely on external partners or licensees to market the drug for treating glaucoma and ocular
02.06.2023 - Press ReleaseNicox: 2023 Ordinary Shareholder MeetingJune 2, 2023 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Paris: FR0013018124, ALCOX), an international ophthalmology company, informs its shareholders that the Ordinary . Seite 1
Press ReleaseNicox's Partner Ocumension Therapeutics Receives Priority Review Status for ZERVIATE New Drug Application in China Nicox's partner, Ocumension Therapeutics, announced on April
Press ReleaseNew Data on Two Nicox's Assets, NCX 470 and NCX 1728, Presented at ARVO 2023April 26, 2023 - release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Paris: FR0013018124, COX), an